ライフサイエンスコーパス: conditioning regimen

1 37) for 2 years, starting at the time of the conditioning regimen.

2 relapse, regardless of the intensity of the conditioning regimen.

3 ing fludarabine and melphalan as the optimal conditioning regimen.

4 nrelated donor, but not the intensity of the conditioning regimen.

5 x 108 CD30.CAR-Ts/m2, were infused without a conditioning regimen.

6 pectively, with no significant difference by conditioning regimen.

7 from an unrelated donor and a myeloablative conditioning regimen.

8 and absence of antithymocyte globulin in the conditioning regimen.

9 were compared as part of a nonmyeloablative conditioning regimen.

10 ognostic stratification and the selection of conditioning regimen.

11 a total body irradiation-based myeloablative conditioning regimen.

12 a direct consequence of the intensity of the conditioning regimen.

13 ide, cytarabine, and cyclophosphamide as the conditioning regimen.

14 differences between donor and recipient, and conditioning regimen.

15 randomized phase 3 study of ATG as part of a conditioning regimen.

16 comes, we made sequential changes to the HCT conditioning regimen.

17 fan and cyclophosphamide was the most common conditioning regimen.

18 A matching, calendar year of transplant, and conditioning regimen.

19 receiving nonmyeloablative HCT or ATG in the conditioning regimen.

20 oietic stem cell transplant recipient during conditioning regimen.

21 ecommendations on the optimal high intensity conditioning regimen.

22 onor if the patient receives a myeloablative conditioning regimen.

23 native donor sources and identifying optimal conditioning regimens.

24 , some of which are related to the intensive conditioning regimens.

25 y reflecting progress in supportive care and conditioning regimens.

26 w transplantation, protocols usually include conditioning regimens.

27 transplantation that uses reduced-intensity conditioning regimens.

28 d T-replete grafts with mostly myeloablative conditioning regimens.

29 irradiation or nonmyeloablative chemotherapy conditioning regimens.

30 ive (n = 155) or reduced intensity (n = 102) conditioning regimens.

31 myeloablative allogeneic SCT with TBI-based conditioning regimens.

32 egimens and those who received myeloablative conditioning regimens.

33 d allogeneic SCT following reduced-intensity conditioning regimens.

34 CT from unrelated donors using myeloablative conditioning regimens.

35 s populations, with dissimilar diagnosis and conditioning regimens.

36 SD-HCT (n = 807) following reduced-intensity conditioning regimens.

37 were too old or infirm to tolerate standard conditioning regimens.

38 imited graft cell number or nonmyeloablative conditioning regimens.

39 n (ATG; n = 491) following reduced-intensity conditioning regimens.

40 d donors; 9 patients received busulfan-based conditioning regimens.

41 oablative and 737 received reduced intensity conditioning regimens.

42 loablative and 88 received reduced intensity conditioning regimens.

43 had comparable mortality risks regardless of conditioning regimens.

44 ophils could amplify tissue damage caused by conditioning regimens.

45 been further increased by reduced-intensity conditioning regimens.

46 not statistically different between the two conditioning regimens.

47 ioning phase or the use of reduced-intensity conditioning regimens.

48 plastic syndrome; 98% received myeloablative conditioning regimens 100% received T-replete grafts, 97

49 ene therapy in CLAD using 2 nonmyeloablative conditioning regimens--200 cGy total body irradiation (T

50 s added to the fludarabine, cyclophosphamide conditioning regimen ((90)YFC).

51 th 149 dUCBT recipients, after myeloablative conditioning regimen adjusting for the differences betwe

52 atopoietic cell transplantation (HCT) is the conditioning regimen administered before the hematopoiet

53 inical reports suggest that nonmyeloablative conditioning regimens afford better outcomes in patients

54 of cytotoxic chemotherapy in the transplant-conditioning regimen, allogeneic T lymphocytes were remo

55 (GVHD) in mice receiving a nonmyeloablative conditioning regimen allowing establishment of mixed hem

56 esults in children following a myeloablative conditioning regimen and a matched sibling donor transpl

57 erapy after a reduced-intensity chemotherapy conditioning regimen and allogeneic hematopoietic stem-c

58 Under a conditioning regimen and GVHD inflammatory settings, MDS

59 Patient 2 experienced skin toxicity from the conditioning regimen and hypertensive crisis that was li

60 ransplantation after a uniform myeloablative conditioning regimen and immunoprophylaxis for graft-ver

61 received a melphalan-based reduced-intensity conditioning regimen and posttransplant cyclophosphamide

62 tion using a short-duration nonmyeloablative conditioning regimen and posttransplant cyclophosphamide

63 rbid conditions, pretransplant chemotherapy, conditioning regimen and source of stem cells, affect tr

64 Modest modifications in the conditioning regimen and supportive care have improved o

65 to the recipient's age, donor selection, the conditioning regimen and the extent of reconstitution.

66 adiation-free GVHD preventative anti-CD3/CD8 conditioning regimen and transplanted with bone marrow (

67 The median age at HCT was 8.7 years; conditioning regimens and allograft sources varied.

68 ity by transplant day 200 varied between the conditioning regimens and donor groups.

69 ntrol at the time of SCT, incorporation into conditioning regimens and finally, using maintenance app

70 this replication attempt, such as different conditioning regimens and I-BET151 doses, are factors th

71 r in patients who received reduced-intensity conditioning regimens and those who received myeloablati

72 TRM, further studies are needed to optimize conditioning regimens and to define the optimal timing o

73 n the expression of PD-1 were induced by the conditioning regimen, and declined after bone marrow tra

74 icenter study with uniform GVHD prophylaxis, conditioning regimen, and donor source, we explored the

75 , there were no complications related to the conditioning regimen, and GVHD did not develop after tra

76 lking, possibly with hypomethylating agents, conditioning regimen, and potential post-HCT treatment,

77 Type of BMT, conditioning regimen, and presence of significant graft

78 em cells, administering an immunosuppressive conditioning regimen, and re-infusing the autologous hae

79 eed for pretransplant chemotherapy, the best conditioning regimen, and the optimal long-term follow-u

80 rticularly those related to genotype, use of conditioning regimen, and use of alternative donors.

81 or acute leukemia, all given a myeloablative conditioning regimen, and with available allele HLA typi

82 Improved donor selection, tailored conditioning regimens, and better supportive care have h

83 lignancies with total-body irradiation (TBI) conditioning regimens, and considered for patients under

84 radiation (TBI) or busulfan/cyclophosphamide conditioning regimens, and received four doses of methot

85 e animal model using 2 clinically applicable conditioning regimens, and they provide support for the

86 The addition of (90)Y to the conditioning regimen appears to be effective in patients

87 Reduced-intensity conditioning regimens are a reasonable alternative for p

88 Reduced-intensity conditioning regimens are associated with a decrease in

89 Thus, reduced-intensity conditioning regimens are being explored.

90 ated mortality; therefore, reduced-intensity conditioning regimens are being used to improve outcomes

91 Nonmyeloablative conditioning regimens are increasingly replacing myeolab

92 encouraging, mostly when thiotepa-containing conditioning regimens are used, both in newly diagnosed

93 ue-specific homing was not solely due to the conditioning regimen, as NK cells proliferated and reach

94 antithymocyte globulin (ATG) as part of the conditioning regimen (ATG group), whereas 579 did not (n

95 mes can be optimized by peritransplant TKIs, conditioning regimen, BCR-ABL monitoring, and relapse ma

96 e combined with a standard reduced-intensity conditioning regimen before allogeneic hematopoietic cel

97 The best conditioning regimen before allogeneic transplantation f

98 eceiving ablative intravenous busulfan-based conditioning regimens before a related or volunteer-unre

99 Bortezomib has also been incorporated into conditioning regimens before autologous stem cell transp

100 y metastases, routinely uses lymphodepletive conditioning regimens before T-cell transfer, like recen

101 y immunodeficiency using a reduced-intensity conditioning regimen between 1998 and 2001.

102 and Australia who received a busulfan-based conditioning regimen between March 18, 2001, and Feb 12,

103 TBI containing conditioning regimens, body mass index >or= 25, and meth

104 a clinically relevant, nonmyeloablative host-conditioning regimen can be used to overcome the immune

105 Treosulfan-containing conditioning regimens can be used safely in HSCT for chi

106 However, only the use of a conditioning regimen capable of ablating functionally de

107 The conditioning regimen caused substantial oxidative stress

108 lentiviral vector after a reduced-intensity conditioning regimen combined with anti-CD20 administrat

109 re given more intense total body irradiation conditioning regimens combined with autologous bone marr

110 omising data have been reported from a novel conditioning regimen combining NMA with ibritumomab tiux

111 o received busulfan-containing myeloablative conditioning regimens, compared with non-Gilbert's syndr

112 For this purpose, we chose a conditioning regimen composed of treosulfan (14 g/m) and

113 For the remaining five patients, the conditioning regimen consisted of cisplatin (25 mg/m(2)

114 For the remaining five patients, the conditioning regimen consisted of cisplatin (25 mg/m2 da

115 The reduced-intensity transplant conditioning regimen consisted of cyclophosphamide and f

116 Conditioning regimens consisted of an alkylating agent a

117 The immune ablative (conditioning) regimen consisted of 200 mg/kg cyclophosph

118 Using our standard conditioning regimen consisting of a specific anti-CD44

119 matopoietic stem cell transplantation with a conditioning regimen consisting of cyclophosphamide and

120 pic lung transplant model, we investigated a conditioning regimen consisting of pretransplant T cell

121 uller et al showed, using a nonmyeloablative conditioning regimen consisting of total lymphoid irradi

122 We have used a nonmyeloablative conditioning regimen consisting of total-body irradiatio

123 The conditioning regimens contained busulfan, cyclophosphami

124 Patients who are scheduled to receive conditioning regimens containing TBI, have a pretranspla

125 ults during the transplant period, including conditioning regimens, corticosteroids, infections, and

126 The low-dose chemotherapy conditioning regimen depleted blood lymphocytes and incr

127 e examined the effect of a reduced-intensity conditioning regimen designed to enhance myeloid engraft

128 s receiving adoptive immunotherapy following conditioning regimens designed to enhance T-cell functio

129 as resulted in the development of less toxic conditioning regimens, designed to allow the benefits of

130 o overcome these limitations, we optimized a conditioning regimen employing anti-CD45 radioimmunother

131 Here, we ask whether a nonmyeloablative conditioning regimen establishing mixed donor-host chime

132 e the development of safer reduced-intensity conditioning regimens, expanded donor pools, advances in

133 bles: patient age, donor type, disease risk, conditioning regimen, FEV1, carbon monoxide diffusion ca

134 igh-dose cyclophosphamide was developed as a conditioning regimen for allogeneic bone marrow transpla

135 We designed a minimal-intensity conditioning regimen for allogeneic hematopoietic cell t

136 evaluate the efficacy of a reduced-intensity conditioning regimen for allogeneic HSC transplantation

137 3-based myeloablation may be used as a novel conditioning regimen for hematopoietic cell transplantat

138 in patients according to age (P = .047), the conditioning regimen for hematopoietic stem cell transpl

139 ndard doses of radioimmunotherapy given as a conditioning regimen for hematopoietic stem-cell transpl

140 yte immune globulin (ATG) in a myeloablative conditioning regimen for patients with acute leukemia wo

141 efficacious, reduced-toxicity, myeloablative-conditioning regimen for patients with AML or MDS underg

142 ent alternative to cyclophosphamide plus TBI conditioning regimen for patients with refractory acute

143 imab (BFR), as a nonmyeloablative allogeneic conditioning regimen for patients with relapsed lymphoma

144 The conditioning regimen for the haemopoietic stem cells was

145 d the recent development of nonmyeloablative conditioning regimens for allogeneic hematopoietic stem

146 have an adjunctive role in nonmyeloablative conditioning regimens for allogeneic stem cell transplan

147 BuCy) are the most widely used myeloablative conditioning regimens for allotransplants.

148 Finally, development of new nontoxic conditioning regimens for HCT that can be safely used in

149 Current myeloablative conditioning regimens for hematopoietic stem cell (HSC)

150 provide an attractive alternative to current conditioning regimens for HSCT in the treatment of non-m

151 y irradiation is a component in various host conditioning regimens for HSCT.

152 phosphamide, the foundation of virtually all conditioning regimens for stem cell transplantation, is

153 dynamics and have implications for design of conditioning regimens for transplantation purposes.

154 hods to humans may enable mild but effective conditioning regimens for transplantation.

155 received allogeneic HCT after high-intensity conditioning regimens for treatment of hematologic malig

156 the use of myeloablative IV-BU vs TBI-based conditioning regimens for treatment of myeloid malignanc

157 h Hurler syndrome (HS) after a myeloablative conditioning regimen from 1995 to 2007.

158 aft-versus-host disease (GVHD), steroid use, conditioning regimens, ganciclovir use, HLA matching, ci

159 r development of GVHD when the pretransplant conditioning regimen generates substantial proinflammato

160 monstrated, likely reflecting differences in conditioning regimens, graft components and posttranspla

161 his complete short-duration nonmyeloablative conditioning regimen had durable lung allograft acceptan

162 stem cell transplantation with conventional conditioning regimens has been associated with significa

163 n addition, utilization of reduced-intensity conditioning regimens has been successful extending acce

164 t of non-myeloablative and reduced-intensity conditioning regimens has enabled older or medically inf

165 The recent advent of these conditioning regimens has limited the assessment of the

166 Reduced-intensity conditioning regimens have allowed the application of tr

167 Low and reduced-intensity conditioning regimens have allowed to transplant growing

168 tudies of BMT in the late 1980s, a number of conditioning regimens have been designed to improve outc

169 Modifications of transplant conditioning regimens have reduced transplant-related mo

170 lopment of nonablative and reduced-intensity conditioning regimens, have enabled the extension of tra

171 nsplantation, particularly reduced-intensity conditioning regimens, have increased the availability o

172 .04) and the inclusion of fludarabine in the conditioning regimen (HR 1.8; P =.07).

173 and in the late phase were nonmyeloablative conditioning regimen (HR, 35.08 [95% CI, 3.90-315.27]),

174 educed intensity compared with myeloablative conditioning regimens (HR 1.36, 1.10-1.68, p=0.0041), tr

175 c cell transplantation (HCT) after high-dose conditioning regimens imposes prohibitively high risks o

176 ng graft-versus-host disease (GVHD) from the conditioning regimen in conjunction with alloreactive do

177 ll patients, we have used a nonmyeloablative conditioning regimen in conjunction with stem cells from

178 alpha-emitter, astatine-211 ((211)At), as a conditioning regimen in dog leukocyte antigen-identical

179 We evaluated a novel alemtuzumab-based conditioning regimen in HSCT for acquired severe aplasti

180 e suggested: use of a fludarabine-containing conditioning regimen in the context of T-cell-depleted m

181 vide support for the use of nonmyeloablative conditioning regimens in preclinical protocols of retrov

182 al because data are scarce on the effects of conditioning regimens in very young patients.

183 BI to the widely used fludarabine, melphalan conditioning regimen, in hopes of reducing relapse and d

184 The conditioning regimen included alemtuzumab, fludarabine,

185 The myeloablative conditioning regimen included busulfan, cyclophosphamide

186 The conditioning regimen included total-body irradiation and

187 Conditioning regimens included cyclophosphamide (CY) and

188 ients were treated with an immunosuppressive-conditioning regimen including thymectomy or thymic irra

189 (+)Foxp3(+) (Treg) compartment after several conditioning regimens, including T cell-depleted and T c

190 For both trials, the transplantation conditioning regimen incorporated cyclophosphamide, flud

191 n the induction of GVHD of the colon linking conditioning regimen-induced mucosal injury and lipopoly

192 Conditioning regimen-induced TEC damage directly contrib

193 ed before and after changes in myeloablative conditioning regimen intensity (high vs. standard intens

194 ed for recipient cytomegalovirus serostatus, conditioning regimen intensity, total nucleated cell dos

195 of this radiation-free and GVHD preventative conditioning regimen is hindered by the cytokine storm s

196 It has gradually been recognized that the conditioning regimen is important but not critical for t

197 This reduced-intensity conditioning regimen is safe and efficacious in high-ris

198 lack of neoplasia, the toxicity of stringent conditioning regimens is difficult to justify, and reduc

199 tioning with standard antithymocyte globulin conditioning regimens, lower rates of acute and chronic

200 ditioning regimen (RIC) with a myeloablative conditioning regimen (MAC) before allogeneic transplanta

201 identical sibling donors after myeloablative conditioning regimens, mainly for hematologic malignanci

202 This antibody-based conditioning regimen may reduce toxicity and late effect

203 Avoidance of high-intensity conditioning regimens may decrease the incidence of allo

204 tuximab and the use of radioimmunotherapy in conditioning regimens may further increase response rate

205 AK1/2 inhibitor therapy in future transplant conditioning regimens may provide an opportunity to over

206 nts and eliminating TBI from transplantation conditioning regimens may reduce the relative risk of tM

207 uggest the possibility that nonmyeloablative conditioning regimens might be effectively used to promo

208 sive, nonmyeloablative melphalan (MEL)-based conditioning regimens (mini-allograft).

209 es lie in determining the safest preparative conditioning regimen, minimizing graft-versus-host disea

210 Absence of TBI in conditioning regimen modifies neither PFS nor OS.

211 Most UCB recipients received a myeloablative conditioning regimen; most MMRDT recipients did not.

212 Most patients received a myeloablative conditioning regimen (n = 873; 87%); the remainder recei

213 %); the remainder received reduced-intensity conditioning regimens (n = 125; 13%).

214 success to progressive modifications of the conditioning regimen; nevertheless, the improvement may

215 splant practices, including the intensity of conditioning regimens, new immunosuppressive therapies,

216 ms' tumor, systemic lupus erythematosus, and conditioning regimen of bone marrow transplant for Hurle

217 hat cGVHD induced by allogeneic HSCT after a conditioning regimen of cyclophosphamide and total-body

218 T cells 2 days after a low-dose chemotherapy conditioning regimen of cyclophosphamide plus fludarabin

219 Patients received a conditioning regimen of fludarabine (30 mg/m(2) daily fo

220 Thirteen patients underwent a conditioning regimen of fludarabine (30 mg/m2 daily for

221 All patients received a conditioning regimen of fludarabine (40 mg/m(2) daily fo

222 ney recipients also received a pretransplant conditioning regimen of four plasmapheresis treatments f

223 er kilogram of body weight after receiving a conditioning regimen of low-dose cyclophosphamide and fl

224 Group II and III received a conditioning regimen of rMamu-IL-12 (10 and 20 microg/kg

225 A post-transplantation conditioning regimen of total lymphoid irradiation and a

226 Using a GVHD protective nonmyeloablative conditioning regimen of total lymphoid irradiation and a

227 were included if they had received high-dose conditioning regimens of cyclophosphamide plus total bod

228 Impact of total-body irradiation (TBI) in conditioning regimen on outcome for patients with mantle

229 effect of a pharmacologic, nonmyeloablative, conditioning regimen on the development of EGFP+ donor/r

230 facilitating the matching of donor type and conditioning regimens, or indeed alternative therapies (

231 ars (P = .003) and after a reduced-intensity conditioning regimen (P = .03).

232 llows: cord blood transplantation (P<0.001), conditioning regimen (P=0.030), acute GVHD (P=0.003), an

233 s remains limited and problematic, but novel conditioning regimens, particularly in the haploidentica

234 as also impacted by patient age, donor type, conditioning regimen, platelet count, and etiology of MD

235 upport the concept that lung damage from the conditioning regimen plays a crucial role in the develop

236 Studies evaluating novel STs, conditioning regimens, post-ASCT maintenance, or allogen

237 ults of childbearing age who receive similar conditioning regimens prior to allogeneic transplantatio

238 In vivo tracking revealed that the conditioning regimen provided a favorable milieu that en

239 odalities are based mainly on high-intensity conditioning regimens, recently introduced reduced-inten

240 We found that total body irradiation, a conditioning regimen required to permit engraftment of a

241 Such conditioning regimens resulted in long-term persistence

242 We conclude that the reduced-intensity conditioning regimen results in improved survival and re

243 Purpose To compare a reduced-intensity conditioning regimen (RIC) with a myeloablative conditio

244 ransplant and utilization of nonmyeloblative conditioning regimens show promising results.

245 cal variables, including underlying disease, conditioning regimen, stem cell donor status, duration a

246 n, NJ), CECs were counted before (T1), after conditioning regimen (T2), at engraftment (T3), at GvHD

247 ultiple myelomas received a nonmyeloablative conditioning regimen that consisted of 60 mg/kg cyclopho

248 in published reports and showed that only a conditioning regimen that contained busulfan was signifi

249 ients were treated with an immunosuppressive conditioning regimen that included thymectomy, splenecto

250 PEX syndrome using a novel reduced-intensity conditioning regimen that resulted in stable donor engra

251 T cells (Tregs) surviving a nonmyeloablative conditioning regimen that undergo robust homeostatic exp

252 Thus, conditioning regimens that augment NK-cell reactivity sh

253 nsplantation, the chemotherapy and radiation conditioning regimens that precede hematopoietic stem ce

254 st candidates for this strategy, the optimal conditioning regimen, the best time for response assessm

255 HD models include the irradiation only-based conditioning regimen, the homogenous donor/recipient gen

256 cells was dependent on the intensity of the conditioning regimen, the leukemic status of the recipie

257 ose, reduced-intensity, and nonmyeloablative conditioning regimens, the most commonly used agents and

258 d mortality associated with nonmyeloablative conditioning regimens, the question of whether a patient

259 necessitated the use of a mild pretransplant conditioning regimen; therefore, in vivo drug selection

260 In patients who received CY/TBI or melphalan conditioning regimens, those with Gilbert's syndrome had

261 ing less intensive, and therefore less toxic conditioning regimens, thus allowing the graft-versus-ma

262 re needed to define optimal intensity of the conditioning regimen, timing of transplantation within a

263 e results of sequential modifications of the conditioning regimen to improve the outcome of unrelated

264 itution, followed several years later with a conditioning regimen to restore B-cell immunity.

265 be safely combined with a reduced-intensity conditioning regimen to yield encouraging overall surviv

266 'Non-myeloablative' conditioning regimens to achieve lymphocytic ablation wi

267 or reduce the need for potentially hazardous conditioning regimens to achieve optimal antitumor respo

268 ative sources of stem cells and a variety of conditioning regimens to achieve their engraftment have

269 We found that radiation in BMT conditioning regimens upregulated expression of the deat

270 ological malignancies, the reduced intensity conditioning regimen used in the context of nonmalignant

271 The conditioning regimen used was CYC (200 mg/kg), antithymo

272 tation outcome irrespective of donor choice, conditioning regimen used, and underlying genetic diagno

273 iagnosis to first relapse and the transplant conditioning regimen used.

274 -TCD (P<0.001), high-intensity myeloablative conditioning regimens used in cohort 1 (P = 0.02), and m

275 However, compared with the stringent conditioning regimens used when performing BMT to treat

276 ndergone transplantation after pretransplant conditioning regimen using plasmapheresis and/or intrave

277 y have been performed with reduced intensity conditioning regimens using unmanipulated peripheral blo

278 A fludarabine and cyclophosphamide-based conditioning regimen was used.

279 ut not recipient age or the intensity of the conditioning regimens, was the most important factor inf

280 o reduce or eliminate total body irradiation conditioning regimens, we have sought to develop canine

281 The conditioning regimens were completed on day -4.

282 Conditioning regimens were heterogeneous, but most were

283 Conditioning regimens were myeloablative (9) and reduced

284 Various conditioning regimens were used, and marrow, peripheral

285 onfounding variables, such as donor type and conditioning regimen, were included in a multivariate re

286 pment of nonmyeloablative or "low-intensity" conditioning regimens, which have expanded the applicati

287 osis) who received an alemtuzumab-containing conditioning regimen who developed autoimmune cytopenias

288 he use of a mobilized blood cell graft and a conditioning regimen with > 450 cGy total body irradiati

289 or acute leukemia underwent an experimental conditioning regimen with 10 doses of total lymphoid irr

290 In this study, we tested a radiation-free conditioning regimen with a T-cell-depleted graft to eli

291 ute myeloid leukemia patients receiving this conditioning regimen with age and disease risk index-mat

292 l trials using (213)Bi as a nonmyeloablative conditioning regimen with minimal toxicity.

293 rary controls (n = 22) who received the same conditioning regimen with sirolimus and mycophenolate mo

294 Six baboons underwent a conditioning regimen with thymectomy, splenectomy, and a

295 TGF-beta-generating recipient Tregs after a conditioning regimen with total body irradiation and led

296 ld receive busulfan-containing myeloablative conditioning regimens with caution.

297 linical outcome using this approach requires conditioning regimens with total body irradiation, lymph

298 arrow ablation have been superseded by safer conditioning regimens, with occasional complete remissio

299 kemia), from a matched family donor, after a conditioning regimen without irradiation, the latter inc

300 mab (4/25), 1.9% for ATG (2/102), and 0% for conditioning regimens without lympho-depleting antibodie